Concepedia

Publication | Open Access

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer

DOIFull Paper Access

65

Citations

21

References

2013

Year

Charles S. Fuchs, Marwan Fakih, Lee S. Schwartzberg, Allen Lee Cohn, Lorrin Yee, Luke Dreisbach, Mark Kozloff, Yong‐jiang Hei, Francesco Galimi, Yang Pan,
Cancer

Abstract

Conatumumab with mFOLFOX6/bev did not offer improved efficacy over the same chemotherapy with placebo in first-line treatment of patients with mCRC. These data do not support further development of conatumumab in advanced CRC.

References

YearCitations

Page 1